New anti-diabetic agents: major advances with unanswered questions

Rev Cardiovasc Med. 2020 Dec 30;21(4):489-492. doi: 10.31083/j.rcm.2020.04.220.

Abstract

No abstract present.

Keywords: Diabetes mellitus; GLP1-RA; SGLT2i; chronic kidney disease; heart failure.

Publication types

  • Editorial

MeSH terms

  • Biomarkers / blood
  • Blood Glucose / drug effects*
  • Blood Glucose / metabolism
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / prevention & control
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / mortality
  • Diabetic Nephropathies / mortality
  • Diabetic Nephropathies / prevention & control
  • Glucagon-Like Peptide-1 Receptor / agonists
  • Humans
  • Incretins / adverse effects
  • Incretins / therapeutic use*
  • Protective Factors
  • Risk Factors
  • Sodium-Glucose Transporter 2 Inhibitors / adverse effects
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*
  • Treatment Outcome

Substances

  • Biomarkers
  • Blood Glucose
  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Incretins
  • Sodium-Glucose Transporter 2 Inhibitors